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Objectives
We sought to compare all-cause mortality of people living with HIV and accessing care in Canada
and the UK.
Methods
Individuals from the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative
HIV Cohort (UK CHIC) study who were aged ≥ 18 years, had initiated antiretroviral therapy (ART)
for the first time between 2000 and 2012 and who had acquired HIV through sexual transmission
were included in the analysis. Cox regression was used to investigate the difference in mortality
risk between the two cohort collaborations, accounting for loss to follow-up as a competing risk.
Results
A total of 19 960 participants were included in the analysis (CANOC, 4137; UK CHIC, 15 823).
CANOC participants were more likely to be older [median age 39 years (interquartile range (IQR): 33,
46 years) vs. 36 years (IQR: 31, 43 years) for UK CHIC participants], to be male (86 vs. 73%,
respectively), and to report men who have sex with men (MSM) sexual transmission risk (72 vs. 56%,
respectively) (all P < 0.001). Overall, 762 deaths occurred during 98 798 person-years (PY) of
follow-up, giving a crude mortality rate of 7.7 per 1000 PY [95% confidence interval (CI): 7.1, 8.3
per 1000 PY]. The crude mortality rates were 8.6 (95% CI: 7.4, 10.0) and 7.5 (95% CI: 6.9, 8.1) per
1000 PY among CANOC and UK CHIC study participants, respectively. No statistically significant
difference in mortality risk was observed between the cohort collaborations in Cox regression
accounting for loss to follow-up as a competing risk (adjusted hazard ratio 0.86; 95% CI: 0.72–1.03).
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Conclusions
Despite differences in national HIV care provision and treatment guidelines, mortality risk did not
differ between CANOC and UK CHIC study participants who acquired HIV through sexual
transmission.
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Introduction
Canada and the UK are two high-income countries with
notable differences in health care provision for people
living with HIV (PLWH). However, whether clinical prog-
noses differ for PLWH receiving care between these two
settings remains undefined.
Ongoing health care and treatment for all 107 800
PLWH in the UK is provided free of charge through the
National Health Service (NHS) [1]. HIV treatment guideli-
nes and standards of care documents published by the
British HIV Association (BHIVA), together with a national
service specification from NHS England, provide a uni-
versal national benchmark to guide clinical HIV care and
prescribing decisions throughout the UK [2,3].
In Canada, there are 75 500 PLWH [4], and although
select provinces provide treatment guidelines, no
acknowledged national standards in HIV care exist. In
British Columbia (BC) and Quebec, HIV treatment is for-
mally standardized by comprehensive provincial guideli-
nes [5,6]. Other Canadian provinces informally follow
International Antiviral Society (IAS) guidelines [7] and/or
recommendations from the US Department of Health and
Human Services [8]. Antiretroviral therapy (ART) funding
mechanisms vary across Canada, ranging from complete
coverage to partial coverage or income-based reimburse-
ment [9–11].
Recent work has shown reduced attrition at all stages of
the HIV care cascade among PLWH in the UK compared
with Canadian settings [12]. In light of the aforementioned
differences in HIV care provision between the UK and
Canada, and emerging disparities in the HIV care cascade
[12], we sought to compare all-cause mortality within a
subset of the populations infected with HIV via sexual
transmission in these two settings. All-cause mortality has
been recognized as a preferred prognostic indicator for
PLWH [13]. This outcome variable was selected as a basic,
easily interpreted measure of cohort health status [13].
Methods
Subsets of data from two national cohort collaborations
investigating HIV clinical outcomes and treatment
responses, the Canadian Observational Cohort (CANOC)
collaboration and UK Collaborative HIV Cohort (CHIC)
study, were merged in September 2014. At this time, data
were available from 1 January 2000 up to the end of
2012 for both cohort collaborations.
CANOC collaboration
The CANOC collaboration is a multi-site cohort of PLWH
initiating ART for the first time after 1 January 2000, and
was established to evaluate patterns of treatment uptake
and response, and health service provision and outcomes
across Canada. Participants must reside in Canada and be
aged at least 18 years, with documented HIV infection.
Each contributing cohort site performs data extraction of
demographic, laboratory and clinical variables, submitted
annually to the coordinating centre in Vancouver for data
merging, cleaning and analysis. At the time of writing,
almost 10 000 participants had contributed data from eight
cohorts located within the country’s most populous pro-
vinces: BC, Ontario and Quebec. The BC cohort submits full
population-level data, whereas sites in Ontario and Quebec
largely capture clinic-based data. Ethics board approval of
the CANOC collaboration was granted to each participating
cohort site. A detailed cohort profile has been published [14].
UK CHIC study
The UK CHIC study is a collaboration that currently
includes 19 participating NHS HIV treatment centres. The
study was established in 2001 with the aim of evaluating
treatment uptake and clinical outcomes of PLWH access-
ing care in the UK [15,16]. The UK CHIC study currently
includes over 50 000 participants aged > 16 years, who
have received HIV care at one of the collaborating cen-
tres in England and Scotland on at least one occasion
since 1996. Each participating centre submits electronic
data annually to the coordinating group based at Univer-
sity College London (UCL) and the Medical Research
Council Clinical Trials Unit. The coordinating group
merges de-identified data into a final data set after per-
forming data cleaning and quality checks. The UK CHIC
study has been approved by a multi-centre research
ethics committee and by local ethics committees. Further
details can be found in the cohort profile [16].
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Inclusion criteria
Participants included in this merged collaborative analy-
sis were aged 18 years or older, initiated ART for the first
time between 2000 and 2012, had complete information
on gender, sexual transmission risk, CD4 cell count and
HIV viral load (VL) prior to ART initiation (baseline), and
had at least one follow-up measure of CD4 cell count and
VL. Participant inclusion was limited to individuals pre-
sumed infected via sexual routes to improve cohort com-
parability, as a consequence of the low prevalence of
individuals who have acquired HIV through injecting
drug use (IDU) in the UK compared with Canada (2 vs.
17%, respectively) [1,17]. Nonetheless, we carried out a
sensitivity analysis including persons with a history of
IDU to evaluate potential bias that may have been intro-
duced as a result of their exclusion from the primary
analysis.
Measures
Primary outcome variable
The primary outcome of interest was all-cause mortality,
defined as date of death. In the UK CHIC study, date of death
is requested as part of the annual data submission from par-
ticipating centres. Additionally, records for the majority
(94%) of UK CHIC participants are linked to National HIV
Surveillance data at Public Health England to supplement
information on deaths. These data sets also receive mortal-
ity information from the Office of National Statistics for
deaths occurring under the age of 65 years in the UK. The
completeness of death ascertainment among UK CHIC study
participants is therefore high. In CANOC, mortality ascer-
tainment varies within participating cohorts. Two of the
eight participating cohorts have established linkages to vital
statistics registries, allowing for excellent ascertainment of
deaths. However, other participating cohorts submit date of
death as part of regular data submission to the coordinating
centre, with no linkage to vital statistics, and consequently
death ascertainment is less complete.
Explanatory variables of interest
Explanatory variables included were age at ART initiation
(per decade), sexual transmission risk category [men who
have sex with men (MSM), heterosexual male or hetero-
sexual female], ethnicity (Caucasian, Black, Asian, other
or unknown), hepatitis C serostatus, defined as hepatitis C
antibody positive at treatment initiation (yes, no or
unknown), baseline diagnosis of AIDS-defining illness
(ADI) (yes or no), baseline CD4 cell count (per 100 cells/
lL) and HIV RNA plasma VL (log10 HIV-1 RNA copies/
mL), composition of initial antiretroviral regimen, and era
of ART initiation (2000–2003, 2004–2007 or 2008–2012).
Loss to follow-up
Cohort studies often fail to accurately classify mortality
outcomes among persons lost to follow-up, resulting in
under-ascertainment of deaths and affecting study valid-
ity [18]. Mortality among persons lost to follow-up is
reported to range from 28 to 40% [19–24]. Other cohort
collaborations have noted considerable variation in the
attrition of cohort participants; the Antiretroviral Therapy
Cohort Collaboration (ART-CC) reported that loss to fol-
low-up varied between participating cohorts from 2 to
18% [19]. We defined loss to follow-up as no clinical
contact for at least 18 months, and accounted for this
important variable as a competing risk in our statistical
analysis. Competing risk analyses maintain participants
in the analysis who are lost to follow-up among those
who are at risk of dying, rather than censoring them at
the last point of clinical contact [25].
Statistical models
Differences in baseline sociodemographic and clinical
characteristics between cohort collaborations were evalu-
ated using chi-square or Fisher’s exact test for categorical
variables and the Wilcoxon rank sum test for continuous
variables. Crude mortality rates were calculated per 1000
person-years (PY) by dividing total deaths by total person-
years of follow-up.
Competing risks Cox regression [25] identified variables
associated with mortality during study follow-up,
accounting for loss to follow-up as a competing risk. Pre-
vious work has shown that all-cause mortality and causes
of death differ with time since ART initiation, with all-
cause mortality highest in the first year following ART
initiation, largely as a result of AIDS-related deaths
[26,27]. We therefore compared mortality rates between
the cohort collaborations within the first year since ART
initiation as well as for the entire follow-up period. Vari-
ables considered likely to have an impact on the risk of
death following literature review and clinical hypothesis
were a priori candidates for model inclusion. Due to the
large proportion of missing data for ethnicity and hepati-
tis C antibody status, these covariates were not included
in the adjusted analysis. An exploratory model selection
process based on the Akaike information criterion and
type III P-values was used to guide final model selection.
Statistical tests were considered significant at a = 0.05.
Analyses were conducted using SAS 9.4 software (SAS
Institute, Cary, NC, USA).
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Sensitivity analysis
Individuals who acquired HIV through IDU represent 17%
of the Canadian population living with HIV [1,17]. As
these individuals were excluded, CANOC participants
included in the main analysis did not fully represent the
Canadian population living with HIV. Previous work has
shown that Canadians with a history of IDU have
increased all-cause mortality rates [28,29]; thus, we were
aware that exclusion of injecting drug users from our
main analysis would underestimate the mortality rate
within CANOC. To generate crude mortality estimates
more accurately representing the Canadian HIV epidemic,
we performed a sensitivity analysis within an analytic
sample that included participants reporting IDU transmis-
sion risk from each cohort collaboration.
Results
Of the 19 960 individuals included in the main analysis,
4137 were CANOC and 15 823 were UK CHIC study par-
ticipants. CANOC participants were older [median
39 years (interquartile range (IQR) 33, 46 years) vs.
36 years (IQR: 31, 43 years) for UK CHIC participants],
and were more likely to be male (86 vs. 73%, respec-
tively) and to report MSM sexual transmission risk (72
vs. 56%, respectively) (all P < 0.001) (Table 1).
Clinical profile
Median baseline CD4 cell count was low across both the
CANOC collaboration and UK CHIC study [230 (IQR: 120,
328) and 219 (IQR: 120, 314) cells/lL, respectively;
P = 0.007] (Table 1). When evaluated across the three
eras of ART initiation (2000–2003, 2004–2007 and 2008–
2012), median baseline CD4 count was found to increase
with more recent ART era within the CANOC collabora-
tion [174 (IQR: 80, 263), 193 (IQR: 107, 270) and 270
(IQR: 170, 357) cells/lL, respectively] and the UK CHIC
study [170 (IQR: 70, 271), 198 (IQR: 109, 266) and 288
(IQR: 180, 390) cells/lL, respectively] (both P < 0.001).
Treatment profile
Initial ART regimen varied significantly between the
cohort collaborations. A larger proportion of UK CHIC
participants initiated a nonnucleoside reverse transcrip-
tase inhibitor (NNRTI) as the third drug class within the
initial regimen compared with CANOC participants (67 vs.
45%, respectively). CANOC participants were significantly
more likely to initiate a regimen including a boosted pro-
tease inhibitor (PI) (42 vs. 23% in UK CHIC) (P < 0.001).
For both CANOC and UK CHIC participants, efavirenz was
most commonly used as the third antiretroviral agent in
the primary regimen (36 vs. 55%, respectively); however,
CANOC participants were more likely than UK CHIC
participants to be prescribed atazanavir (22 vs. 7%,
respectively) (P < 0.001). Era of ART initiation differed
slightly between cohort collaborations, with a greater
proportion of UK CHIC participants initiating ART in the
era 2004–2007 compared with CANOC participants (33
vs. 31%, respectively; P = 0.003) (Table 1).
Loss to follow-up
In total, 2548 participants were lost to follow-up over a
period of 98 798 PY, to give an attrition rate of 25.8
[95% confidence interval (CI) 24.8, 26.8] per 1000 PY.
When stratified by cohort collaboration, the attrition rates
were 26.9 (95% CI: 24.7, 29.2) and 25.5 (95% CI: 24.4,
26.7) per 1000 PY for CANOC and the UK CHIC study,
respectively.
Mortality during total follow-up period
There were 762 deaths during a total follow-up time of
98 798 PY, giving a crude mortality rate of 7.7 (95% CI:
7.1, 8.3) per 1000 PY. When stratified by cohort collabo-
ration, the mortality rate was 8.6 (95% CI: 7.4, 10.0) per
1000 PY among CANOC participants, and 7.5 (95% CI:
6.9, 8.1) per 1000 PY among UK CHIC participants (Fig-
ure 1). In the competing risk survival analysis, no statisti-
cally significant difference in mortality was observed
between the cohort collaborations after adjusting for par-
ticipant age, era of ART initiation, sexual transmission
risk category, CD4 cell count and VL at treatment initia-
tion, and initial ART regimen [adjusted hazard ratio
(AHR) 0.86; 95% CI: 0.72, 1.03] (Table 2a). Notably, the
direction of the cohort effect on mortality was seen to
reverse in the adjusted analysis, which was largely attrib-
uted to adjustment for participant age.
Mortality in the year after ART initiation
There were 220 deaths during the first year after ART ini-
tiation, giving a crude mortality rate of 2.2 (95% CI: 1.9,
2.5) per 1000 PY. When stratified by cohort collaboration,
the mortality rate within the first year after ART initia-
tion was 2.2 (95% CI: 1.6, 2.9) per 1000 PY among
CANOC participants, and 2.2 (95% CI: 1.9, 2.6) per 1000
PY among UK CHIC participants. In competing risk sur-
vival analysis there was no statistically significant differ-
ence in mortality in the year after ART initiation between
CANOC and UK CHIC participants after adjusting for
confounders (AHR 0.71; 95% CI: 0.50, 1.01) (Table 2b).
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Sensitivity analysis
When we included participants with IDU transmission
risk, 2282 participants were added to the original
analytic sample: 1934 additional CANOC participants
and 348 additional UK CHIC participants (see Sup-
porting Information Tables). There were 1161 deaths
during a total follow-up time of 110 414 PY, producing
a crude mortality rate of 10.5 (95% CI: 9.9, 11.1) per
1000 PY. When stratified by cohort collaboration, the
mortality rate was 17.0 (95% CI: 15.6, 18.6) per 1000
PY among CANOC participants, and 8.0 (95% CI: 7.4,
8.7) per 1000 PY among UK CHIC participants. In a
competing risk survival analysis, no significant differ-
ence in mortality was observed between the cohort
collaborations (AHR 0.9; 95% CI: 0.8, 1.1) after adjust-
ing for confounders (see Supporting Information
Tables).
Table 1 Comparison of sociodemographic and clinical characteristics for the Canadian Observational Cohort (CANOC) and UK Collaborative
HIV Cohort (UK CHIC) study (n = 19 960)
Characteristic Category
CANOC and UK CHIC
n (%) or median (IQR)
CANOC (n = 4137)
n (%) or median (IQR)
UK CHIC (n = 15 823)
n (%) or median (IQR) P-value
Gender Male 15072 (76) 3572 (86) 11500 (73) < 0.001
Female 4888 (24) 565 (14) 4323 (27)
Age at ART initiation (years) – 37 (31,44) 39 (33,46) 36 (31,43) < 0.001
HIV sexual transmission risk MSM 11842 (59) 2985 (72) 8857 (56) < 0.001
Heterosexual male 3230 (16) 587 (14) 2643 (17)
Heterosexual female 4888 (24) 565 (14) 4323 (27)
Ethnicity Caucasian 9999 (50) 1569 (38) 8430 (53) < 0.001
Black 6272 (31) 547 (13) 5725 (36)
Asian 713 (4) 202 (5) 511 (3)
Mixed 689 (3) 93 (2) 596 (4)
Other 846 (4) 285 (7) 561 (4)
Unknown 1441 (7) 1441 (35) 0
Hepatitis C virus positive No 10578 (53) 748 (18) 9830 (62) < 0.001
Yes 546 (3) 129 (3) 417 (3)
Unknown 8836 (44) 3260 (79) 5576 (35)
Baseline CD4 count (cells/lL) – 220 (120,318) 230 (120,328) 219 (120, 314) 0.007
Baseline VL (log10 copies/mL) – 5 (4, 5) 5 (4, 5) 5 (4, 5) 0.06
ADI at baseline No 17040 (85) 4365 (84) 13575 (86) 0.001
Yes 2920 (15) 672 (16) 2248 (14)
Third drug class in first regimen NNRTI 12453 (62) 1858 (45) 10595 (67) < 0.001
Single PI 718 (4) 255 (6) 463 (3)
Boosted PI 5395 (27) 1753 (42) 3642 (23)
NRTI 303 (2) 84 (2) 219 (1)
Other 1091 (5) 187 (5) 904 (6)
Third drug in first regimen Efavirenz 10148 (51) 1478 (36) 8670 (55) < 0.001
Nevirapine 2136 (11) 309 (7) 1827 (12)
Lopinavir 2284 (11) 618 (15) 1666 (11)
Atazanavir 1997 (10) 902 (22) 1095 (7)
Nelfinavir 346 (2) 148 (4) 198 (1)
Saquinavir 340 (2) 53 (1) 287 (2)
Other 1091 (14) 629 (15) 2080 (13)
NRTI backbone of first regimen Tenofovir/emtricitabine 9262 (46) 1762 (43) 7500 (47) < 0.001
Zidovudine/lamivudine 4550 (23) 938 (23) 3612 (23)
Tenofovir/lamivudine 793 (4) 257 (6) 536 (3)
Abacavir/lamivudine 2719 (14) 677 (16) 2042 (13)
Stavudine/lamivudine 579 (3) 291 (7) 288 (2)
Other 2057 (10) 212 (5) 1845 (12)
Era ART initiated 2000–2003 4827 (24) 1021 (25) 3806 (24) 0.003
2004–2007 6540 (33) 1266 (31) 5274 (33)
2008–2012 8593 (43) 1850 (45) 6743 (43)
Lost to follow-up* Yes 2548 (13) 556 (13) 1992 (13) 0.1
No 17412 (87) 3581 (87) 13831 (87)
Died during follow-up Yes 762 (4) 179 (4) 583 (4) 0.06
No 19198 (96) 3958 (96) 15240 (96)
Total years of follow-up – 4 (2, 8) 4 (2, 8) 4 (2, 8) 0.30
ADI, AIDS-defining illness; VL, viral load; ART, antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with men; NNRTI, nonnucleoside
reverse transcriptase inhibitor; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Column totals may not consistently add up to 100% because of rounding.
*Loss to follow-up is defined as no clinical contact for ≥ 18 months.
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Discussion
This analysis presents a novel comparison of sociodemo-
graphic and clinical profiles and mortality outcomes for
individuals living with HIV and accessing ART within
two high-income settings: Canada and the UK. Despite
differences in national HIV care provision, treatment
guidelines, and clinical characteristics, mortality risk did
not differ significantly between CANOC and UK CHIC
study participants in Cox regression accounting for loss
to follow-up as a competing risk.
Baseline clinical profile
No clinically relevant differences in baseline CD4 cell
count, VL and ADI prevalence were observed between
CANOC and UK CHIC study participants within our
main analysis. We hypothesized that differences were
probably minimized by limiting our analysis to partici-
pants acquiring HIV through sexual transmission. How-
ever, the baseline clinical profile across cohort
collaborations remained largely unchanged when partic-
ipants reporting HIV acquisition through IDU were
included within a sensitivity analysis. Within both
cohort collaborations, CD4 cell count at treatment initi-
ation, an important indicator of timing of treatment ini-
tiation, increased significantly with more recent
treatment initiation era, reflecting evolving treatment
guidelines over the period of analysis [2,30–32].
Treatment profile
Initial ART regimens differed between CANOC and UK
CHIC participants, with CANOC participants being more
likely to initiate boosted PI-based regimens compared
with UK CHIC participants. Both the ‘third’ drug in the
initial treatment regimen and the backbone regimen also
varied between cohort collaborations. While current treat-
ment guidelines followed in UK and Canadian settings
are broadly consistent, recommending two nucleoside
reverse transcriptase inhibitors (NRTIs) plus an NNRTI or
boosted PI as the initial third agent, the specific antiretro-
viral recommendations vary [2,7,8]. As well as being
influenced by treatment guidelines, prescribing patterns
may be based on the availability of regimens and drug
costs across different settings, as well as patient and pro-
vider preferences.
The variation in treatment regimens observed in this
analysis may also reflect earlier treatment guidelines
within respective cohort collaboration settings. A slightly
Table 2 Competing risk Cox regression of time to death (a) during
entire follow-up period, and (b) in the year after antiretroviral ther-
apy (ART) initiation, with loss to follow-up as a competing risk
(n = 19 960)
Unadjusted
HR (95% CI)
Adjusted
HR (95% CI)
(a)
Cohort Collaboration
UK CHIC 1.00 1.00
CANOC 1.15 (0.98, 1.36) 0.86 (0.72, 1.03)
Age at ART initiation (per decade) 1.69 (1.59, 1.80) 1.67 (1.56, 1.78)
Sexual transmission risk
MSM 1.00 1.00
Heterosexual male 1.50 (1.26, 1.79) 1.15 (0.96, 1.39)
Heterosexual female 0.88 (0.73, 1.10) 0.97 (0.80, 1.18)
Baseline CD4 count (per 100 cells/lL) 0.78 (0.73, 0.84) 0.84 (0.78, 0.91)
Baseline VL (log10 copies/mL) 1.53 (1.28, 1.84) 1.17 (0.97, 1.42)
Third drug in first ART regimen
Efavirenz 1.00 1.00
Lopinavir 1.36 (1.10, 1.69) 1.36 (1.09, 1.69)
Nevirapine 1.08 (0.87, 1.34) 1.13 (0.90, 1.42)
Atazanavir 1.08 (0.81, 1.44) 1.22 (0.89, 1.66)
Other 1.46 (1.21, 1.76) 1.45 (1.18, 1.77)
Backbone of first ART regimen
Tenofovir/emtricitabine 1.00 1.00
Zidovudine/lamivudine 1.43 (1.17, 1.75) 1.36 (1.03, 1.81)
Abacavir/lamivudine 1.48 (1.15, 1.90) 1.43 (1.08, 1.90)
Other 2.04 (1.67, 2.49) 1.64 (1.24, 2.16)
Era of ART initiation
2000–2003 1.00 1.00
2004–2007 0.78 (0.66, 0.91) 0.88 (0.72, 1.07)
2008–2012 0.57 (0.46, 0.70) 0.84 (0.62, 1.15)
(b)
Cohort Collaboration
UK CHIC 1.00 1.00
CANOC 0.97 (0.7, 1.35) 0.71 (0.50, 1.01)
Age at ART initiation (per decade) 1.62 (1.44, 1.82) 1.51 (1.34, 1.71)
Sexual transmission risk
MSM 1.00 1.00
Heterosexual male 2.08 (1.53, 2.83) 1.35 (0.97, 1.86)
Heterosexual female 0.96 (0.68, 1.36) 0.85 (0.59, 1.22)
Baseline CD4 count (per 100 cells/lL) 0.61 (0.54, 0.69) 0.65 (0.57, 0.74)
Baseline VL (log10 copies/mL) 1.53 (1.13, 2.06) 1.04 (0.78, 1.39)
Third drug in first ART regimen
Efavirenz 1.00 1.00
Lopinavir 1.83 (1.24, 2.69) 1.81 (1.22, 2.7)
Nevirapine 0.68 (0.38, 1.22) 0.73 (0.4, 1.32)
Atazanavir 1.36 (0.84, 2.19) 1.5 (0.9, 2.49)
Other 2.45 (1.78, 3.39) 2.66 (1.89, 3.73)
Backbone of first ART regimen
Tenofovir and emtricitabine 1.00 1.00
Zidovudine and lamivudine 1.08 (0.75, 1.56) 1.37 (0.85, 2.21)
Abacavir and lamivudine 1.61 (1.09, 2.38) 1.72 (1.13, 2.63)
Other 1.8 (1.28, 2.53) 1.55 (0.99, 2.41)
Era of ART initiation
2000–2003 1.00 1.00
2004–2007 1.02 (0.74, 1.42) 1.17 (0.79, 1.72)
2008–2012 0.83 (0.59, 1.17) 1.32 (0.82, 2.14)
ADI, AIDS-defining illness; CI, confidence interval; HR, hazard ratio;
VL, viral load; MSM, men who have sex with men; NNRTI, nonnucle-
oside reverse transcriptase inhibitor; PI, protease inhibitor; CANOC,
Canadian Observational Cohort; UK CHIC, UK Collaborative HIV
Cohort.
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higher proportion of UK CHIC participants initiated ART
between 2004 and 2007 compared with CANOC partici-
pants. Treatment guidelines published by BHIVA in 2003
[33] and 2005 [34] recommended NNRTIs over boosted
PIs as the third ART agent, which could account for the
comparatively low use of boosted PIs within UK CHIC
overall. In contrast, the US Department of Health and
Human Services (DHHS) treatment guidelines from 2003
and 2005 recommended both NNRTI-based regimens and
PI-based regimens as equally acceptable initial ART regi-
mens [35,36].
Mortality
According to World Health Organization (WHO) data from
2013, the adult all-cause mortality rate among those aged
15 to 60 years in Canada is lower than in the UK (0.66 vs.
0.72 per 100 000 people, respectively) [37]. However,
2011 reports suggest that Canada has a higher HIV/AIDS-
specific mortality rate (1.1 vs. 0.8 per 100 000 people,
respectively) [38]. Our analysis found that all-cause mor-
tality rates among CANOC and UK CHIC study participants
were not significantly different both within the first year
following ART initiation and during the entire follow-up
period, after adjusting for confounding variables and
accounting for loss to follow-up as a competing risk.
Limited studies have explored differences in all-cause
mortality rates among individuals living with HIV in
Canada and the UK. A recent publication evaluated
between-cohort heterogeneity among participating cohorts
within the ART-CC, and reported a higher all-cause mortal-
ity rate within the North American cohorts compared with
European cohorts, even after accounting for perceived
completeness of ascertainment of mortality, loss to follow-
up and baseline sociodemographic and clinical characteris-
tics [19]. This finding was attributed to the higher propor-
tion of socially marginalized individuals within North
American study cohorts, who were incorrectly adjusted for
in the analysis as a consequence of missing transmission
risk data [19]. We attempted to adjust for the higher pro-
portion of socially marginalized participants in the CANOC
collaboration by limiting inclusion to participants report-
ing sexual transmission risk. However, we were unable to
control for participant ethnicity, a key marker of socioeco-
nomic variation and access to care within both collabora-
tion settings, due to the large proportion of missing data
within the CANOC data set.
In line with our findings, previous work has suggested
that differences in sociodemographic and clinical charac-
teristics and health service provision between HIV-posi-
tive cohorts may have less impact on mortality following
initiation of modern ART regimens. A collaborative
cohort study comparing mortality rates between PLWH in
high- and low-income settings observed that, despite
baseline differences in sociodemographic, clinical and
HIV health service factors, participants demonstrated sim-
ilar treatment outcomes and mortality rates in the two
settings after ART initiation [39].
Additional factors significantly associated with
increased all-cause mortality risk in our analysis included
older age at ART initiation and lower CD4 cell count at
ART initiation. These findings are consistent with previ-
ous mortality analyses within international cohort collab-
orations [39–42], and support the consensus that ART
should be initiated early in the clinical disease course to
optimize clinical outcomes [43,44]. While there appeared
Fig. 1 KaplanMeier plot showing time to death stratified by cohort collaboration (n = 19 960). ART, antiretroviral therapy; CANOC, Canadian
Observational Cohort; UK CHIC, UK Collaborative HIV Cohort.
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to be a nominal decrease in mortality with advancing era
of ART initiation in both the CANOC and UK CHIC stud-
ies, era of ART initiation did not significantly affect all-
cause mortality in the adjusted competing risks survival
analysis. Previous studies in North American [41], Euro-
pean [45] and multinational Euro-North American set-
tings [40] have reported decreased mortality in modern
calendar periods. Our findings may signify that changes
in mortality risk by era are attributed to the introduction
of modern antiretroviral regimens.
Limitations
Readers should be aware of several limitations of our
analysis. We excluded participants who acquired HIV
through IDU from the main analysis to improve cohort
comparability. However, MSM who reported IDU as a sec-
ondary transmission risk category could not be identified
within the UK CHIC study and were coded as MSM, thus
were not excluded from the main analysis. Due to the
low prevalence of IDU among PLWH in the UK CHIC
study, the misclassification is unlikely to have caused a
considerable bias in our findings.
Completeness of death ascertainment varied across par-
ticipating cohorts, with the majority of UK CHIC study mor-
tality data supported by linkages to national vital statistics
databases, and weaker vital statistics linkage capabilities
overall within the CANOC collaboration. We hypothesize
that the weaker ascertainment of death in the CANOC col-
laboration may contribute to the numerically lower mortal-
ity rates seen among CANOC participants in the
multivariable analyses. A final limitation was the lack of
cause-specific mortality data within this analysis. As cause-
specific mortality data were not consistently collected
across all cohorts, we were unable to differentiate between
all-cause and HIV-specific mortality in this analysis.
Conclusions
Among participants enrolled in two longitudinal, multi-
site clinical HIV-positive cohorts in Canada and the UK
who acquired HIV though sexual transmission routes, we
observed no statistically significant difference in all-cause
mortality between cohort collaborations, despite varying
approaches to clinical care and characteristics of PLWH
across the two study settings.
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